Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

AptarGroup, Inc.

ATR

FAVORABLE

May 27, 2026

Research Conclusion

ACCUMULATE at $114-125 | ADD <$98 | HOLD to $165 | TRIM >$200. At ~$114.67/share, ATR trades at 15.9x FY2027E EPS — the first year of EM-normalized earnings — a meaningful discount for a specialty Pharma drug delivery compounder with FDA NDA lock-in moats, 11%+ ROIC, and a GLP-1 tailwind not yet reflected in reported numbers. The 2026 Narcan/EM destocking headwind creates a trough-EPS optic ($5.70 FY2026E vs. $5.89 FY2025A) that makes the stock look expensive at 20x P/E when it is actually cheap on normalized earnings. PWFV is ~$180/share (+57%), supported by 4 Buy-rated analysts at a $170.50 average target. The thesis: EM normalizes in 2027, Pharma mix-shift continues, margins expand from 19.5% to 21.5%+, and the multiple re-rates from 20x packaging to 22-26x Pharma device. The primary risk is the CEO transition (Touya replaces Tanda September 2026) and execution continuity.

Company Overview & Moat Assessment

AptarGroup, Inc. (NYSE: ATR) is the world's leading independent specialist in drug delivery and consumer dispensing systems — precision-engineered pumps, valves, and actuators for pharmaceutical, beauty, and food/beverage applications. Three segments: Pharma (~44% revenue, highest margin; nasal sprays, inhalation, injectables, ophthalmic), Beauty+Home (~30%; personal care and fragrance dispensers), and Closures (~26%; food/beverage caps). Founded in 1992, ATR's competitive advantage in Pharma is the FDA NDA lock-in: ATR co-develops its dispensing systems with pharmaceutical formulations, and once included in the regulatory dossier, changing it requires new clinical validation — effectively locking ATR in for the drug's commercial lifecycle. GLP-1 auto-injectors and wearable injector platforms (Enable Injections partnership) are the incremental growth catalyst for the next decade. Revenue $3.78B in FY2025 with $393M net income; ~64M shares; market cap ~$7.3B.

▲ Bull Case

  • ◆GLP-1 auto-injector wins confirm: Enable Injections partnership captures 10-15% of on-body injector volume by FY2028; $80-120M incremental revenue at Pharma margins; Pharma mix reaches 50%+; adj. EBITDA margin expands to 22-23%; 25x FY2028E $9.50 = $238 (+107%).
  • ◆EM clears fast + CEO continuity: Narcan destocking finishes Q2 2027; Pharma shows 11%+ growth in H2 2027; Touya's first investor day outlines GLP-1 TAM quantification; multiple re-rates from 20x to 25x on Pharma story clarity.
  • ◆M&A discipline continues: Touya executes only targeted Pharma bolt-ons (<$200M each) rather than transformative deals; ROIC expansion continues; stock reaches $220-240 by FY2029.

▼ Bear Case

  • ◆EM extends into FY2027: Narcan OTC inventory normalization takes 18 months; FY2027E EPS $6.50-7.00 (not $7.20); thesis delayed 12-18 months; stock stays near $115-130 through mid-2027.
  • ◆CEO Touya disrupts Pharma co-development: Reorganization disrupts key account relationships; Pharma growth slows to 5-6%/yr; multiple stays compressed at 17x; FY2028E $7.00 × 17x = $119 (+4%).
  • ◆USD strengthening + FX headwind: EUR/USD falls to 0.97-1.00; 50-55% European revenue = $0.25-0.40/share annual EPS headwind; margin expansion offset by FX; FY2028E EPS $7.50-8.00 (not $8.50).
Primary Debate on Wall Street

“Bulls view ATR as a high-quality Pharma-packaging compounder at trough-earnings pricing: EM is one-time, GLP-1 acceleration is the next leg, and 4 Buy analysts at $170 avg PT imply significant upside from $115. Bears and neutrals flag the CEO transition as the key unknown, potential for EM to drag longer than one year, structural FX headwinds from European revenue concentration, and an optically expensive 20x FY2026E P/E — arguing to wait for FY2027 guidance clarity. The decisive question: when Touya delivers his first FY2026 full-year earnings in February 2027, does he (a) confirm the Pharma mix-shift strategy, (b) raise FY2027 EPS guidance above $7.00, and (c) quantify the GLP-1 opportunity? If yes to all three, ATR re-rates immediately toward $160-175.”

Top Catalysts
  • ◆C-01: Q3 2026 earnings confirm EM headwind is H1-concentrated (August 2026) — +15-20%
  • ◆C-02: Touya's first investor day with GLP-1 TAM quantification (H1 2027) — +20-30%
  • ◆C-03: FY2026 full-year EPS guidance above $5.70 / EM beats (February 2027) — +10-15%
  • ◆C-04: FY2027E EPS guidance ≥$7.00 confirming EM normalization (Q4 2026 earnings) — +20-25%
  • ◆C-05: GLP-1 auto-injector revenue disclosed for first time (FY2027 annual report) — +15-20%
  • ◆C-06: Buyback pace accelerates above $200M in a single year (any quarter) — +5-8%
Top Risks
  • ◆R-01: CEO transition disrupts Pharma co-development relationships (Severity: MEDIUM-HIGH, Prob: 20%)
  • ◆R-02: EM headwind extends 18+ months beyond base case (Severity: MEDIUM, Prob: 25%)
  • ◆R-03: FX headwinds from USD strength; EUR/USD <1.00 (Severity: MEDIUM, Prob: 25%)
  • ◆R-04: GLP-1 competitor wins displace ATR platforms (BD, Gerresheimer) (Severity: MEDIUM, Prob: 20%)
  • ◆R-05: Transformative M&A >$1B destroys capital and management focus (Severity: HIGH if triggered, Prob: 10%)
  • ◆R-06: Beauty+Home secular decline from dispensing format disruption (Severity: LOW, Prob: 10%)

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/ATR/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.